IMS 2186 – 25 mg

Brand:
Cayman
CAS:
1031206-36-6
Storage:
-20
UN-No:
De Minimis - 3077 / 9

IMS 2186 is an anti-choroidal neovascularization agent.{57084} It inhibits proliferation of NIH3T3 mouse and IMR-90 human fibroblasts (IC50s = 0.5-3 µM), as well as in a panel of eight human cancer cell lines, including ovarian, lung, colon, and pancreatic cancer cells (IC50s = 0.3-3 µM). IMS 2186 (10 µM) decreases migration of THP-1 macrophages in wound healing and chamber assays. Subcutaneous administration of IMS 2186 (20 µg/animal) inhibits VEGF-induced blood vessel formation in a MatrigelTM plug assay in mice. It reduces ocular leakage, as well as cellular proliferation and infiltration in a rat model of laser-induced choroidal neovascularization when administered intravitreally at a dose of 100 µg/eye.  

 

Available on backorder

SKU: 31157 - 25 mg Category:

Description

An anti-choroidal neovascularization agent; inhibits proliferation of NIH3T3 mouse and IMR-90 human fibroblasts (IC50s = 0.5-3 µM), as well as in a panel of eight human cancer cell lines (IC50s = 0.3-3 µM); decreases migration of THP-1 macrophages in wound healing and chamber assays at 10 µM; inhibits VEGF-induced blood vessel formation in a MatrigelTM plug assay in mice at 20 µg/animal; reduces ocular leakage, as well as cellular proliferation and infiltration in a rat model of laser-induced choroidal neovascularization at 100 µg/eye


Formal name: (3E)-2,3-dihydro-3-[(3-hydroxy-4-methoxyphenyl)methylene]-6-methyl-4H-1-benzopyran-4-one

Synonyms: 

Molecular weight: 296.3

CAS: 1031206-36-6

Purity: ≥98%

Formulation: A solid